Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (paneth cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: varespladib methyl, varespladib | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 7 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 12036
Sealed predictions
- PLA2G2A in dopamine neurons, braak-0.77 (p 0.016) → +0.33 (p 0.389)receipt 12042
Swarm cases
receipt 12042: PLA2G2A in dopamine neurons, braak
- power
- full sample -0.22 (p 0.379, n 18), 95% CI -0.62 to +0.27. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.28 (p 0.258, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.55 (p 0.018, n 18). not the mix.
- skeptic
- leave-one-out range -0.33 to -0.13, sign flips 0; without severely affected donors -0.22 (p 0.379, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PLA2G2A in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts